What people want from sex and preexposure prophylaxis
- PMID: 26569183
- PMCID: PMC6446930
- DOI: 10.1097/COH.0000000000000216
What people want from sex and preexposure prophylaxis
Abstract
Purpose of review: As demand for preexposure prophylaxis (PrEP) increases, we are learning more about what people want from sex and PrEP.
Recent findings: PrEP demand has reached a tipping point in the USA and is increasing rapidly. Although the primary benefit of PrEP use is biological, to reduce risk of HIV infection, PrEP users often express an alternative set of social and emotional benefits that are provided by PrEP. These collateral benefits of PrEP have salience, affect, and are experienced in the present, which are compelling drivers of human behavior. PrEP use has been associated with feeling safe during sex, usually in contrast to ruminations related to fear of HIV or intimate partner violence or control. PrEP can create empowerment, or agency, defined as the capacity and autonomy to act on one's own behalf, because it provides control over one's vulnerability to HIV and relief to women and men who may otherwise worry about whether their partners will use a condom, take antiretroviral therapy, or disclose their HIV status accurately. Planning for sexual and social goals in calm moments is also empowering. These highly desired collateral benefits of PrEP could be undermined, or eliminated, if PrEP is implemented in ways that are coercive or that foment fear of sexual risk compensation, drug resistance, toxicity, or moral judgment.
Summary: Current PrEP implementation provides direct and indirect benefits that are highly desired.
Conflict of interest statement
References
-
- Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. The New England journal of medicine. 2010. December 30;363(27):2587–99. PubMed PMID: . Pubmed Central PMCID: 3079639. Epub 2010/11/26. eng. - PMC - PubMed
-
- Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012. August 2;367(5):423–34. PubMed PMID: . Epub 2012/07/13. eng. - PubMed
-
- Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013. June 15;381(9883):2083–90. PubMed PMID: . - PubMed
-
- Bush S, Ng L, Magnuson D, Piontkowsky D, Mera Giler R, editors. Significant Uptake of Truvada for Pre-exposure Prophylaxis (PrEP) Utilization in the US in Late 2014 – 1Q 2015. IAPAC Treatment, Prevention, and Adherence Conference; 2015; Miami, FL.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
